Targeting leukemogenic gene expression via chromatin regulatory complexes

Research website

Positions held

  • Since 2022: Professor (W2) for Molecular Mechanisms and Translational Epigenetics in Acute Leukemias, University Medical Center (UMC), Mainz
  • Since 2020: Head of Acute Myeloid Leukemia Program, University Medical Center (UMC), Mainz
  • Since 2017: Emmy Noether Program Investigator (DFG), University Medical Center, (UMC), Mainz
  • Since 2017: Attending Physician, University Medical Center (UMC), Mainz
  • Since 2016: Group Leader and Instructor in Medicine, III. Department of Medicine, University Medical Center (UMC), Mainz
  • 2013 - 2015:  Postdoctoral Research Fellow (DFG Scholar), Memorial Sloan Kettering Cancer Center NY, USA
  • 2012: Clinical and Research Fellow (Hematology and Oncology), III. Department of Medicine, University Hospital of Ulm
  • 2007 - 2012: Resident Physician (Internal Medicine), III. Department of Medicine, University Hospital of Ulm

Education

  • 2008: Doctoral Thesis ("summa cum laude"), Institute of Pathology, Free University of Berlin
  • 2007: United States Medical Licensing Examination, Step 2
  • 2006: Licensing degree to practice Medicine in Germany

Selected publications by Michael Kühn

Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, Taubert MC, McGeehan GM, Chen C, Mupo A, Hähnel PS, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, and Kühn MWM (2020) Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. Blood, 136(21):2442-2456 Link

Kühn MWM, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Rahnamay Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, McGeehan G, Vassiliou GS, Hoshii T, and Armstrong SA (2016) Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery, 6(10):1166-1181 Link

Kühn MWM*, Hadler MJ*, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM, Armstrong SA (2015) MLL-PTD leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica, 100(5):e190-3 (*indicates equal contribution) Link 

Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood. 2012 Nov 1;120(18):e83-92. Link

Kühn MWM*, Radtke I*, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H* and Downing JR* (2012) High resolution genomic profiling of adult and pediatric Core-Binding Factor Acute Myeloid Leukemia reveals new recurrent alterationsBlood, 119, e67-75 (* indicates equal contribution) Link